Literature DB >> 33738759

Comparison between Patients Hospitalized with Influenza and COVID-19 at a Tertiary Care Center.

Michael W Donnino1,2, Ari Moskowitz3,4, Garrett S Thompson3, Stanley J Heydrick3, Rahul D Pawar3, Katherine M Berg4, Shivani Mehta3, Parth V Patel3, Anne V Grossestreuer3.   

Abstract

BACKGROUND: Widespread reports suggest the characteristics and disease course of coronavirus disease 2019 (COVID-19) and influenza differ, yet detailed comparisons of their clinical manifestations are lacking.
OBJECTIVE: Comparison of the epidemiology and clinical characteristics of COVID-19 patients during the pandemic with those of influenza patients in previous influenza seasons at the same hospital
DESIGN: Admission rates, clinical measurements, and clinical outcomes from confirmed COVID-19 cases between March 1 and April 30, 2020, were compared with those from confirmed influenza cases in the previous five influenza seasons (8 months each) beginning September 1, 2014.
SETTING: Large tertiary care teaching hospital in Boston, MA PARTICIPANTS: Laboratory-confirmed COVID-19 and influenza inpatients MEASUREMENTS: Patient demographics and medical history, mortality, incidence and duration of mechanical ventilation, incidences of vasopressor support and renal replacement therapy, and hospital and intensive care admissions.
RESULTS: Data was abstracted from medical records of 1052 influenza patients and 582 COVID-19 patients. An average of 210 hospital admissions for influenza occurred per 8-month season compared to 582 COVID-19 admissions over 2 months. The median weekly number of COVID-19 patients requiring mechanical ventilation was 17 (IQR: 4, 34) compared to a weekly median of 1 (IQR: 0, 2) influenza patient (p=0.001). COVID-19 patients were significantly more likely to require mechanical ventilation (31% vs 8%) and had significantly higher mortality (20% vs. 3%; p<0.001 for all). Relatively more COVID-19 patients on mechanical ventilation lacked pre-existing conditions compared with mechanically ventilated influenza patients (25% vs 4%, p<0.001). Pneumonia/ARDS secondary to the virus was the predominant cause of mechanical ventilation in COVID-19 patients (94%) as opposed to influenza (56%). LIMITATION: This is a single-center study which could limit generalization.
CONCLUSION: COVID-19 resulted in more weekly hospitalizations, higher morbidity, and higher mortality than influenza at the same hospital.

Entities:  

Keywords:  COVID-19; influenza; mechanical ventilation

Year:  2021        PMID: 33738759      PMCID: PMC7971402          DOI: 10.1007/s11606-021-06647-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


INTRODUCTION

Coronavirus disease 2019 (COVID-19) and influenza are contagious viral diseases characterized by pneumonia and acute respiratory failure in severe cases. Both place a burden on the health care system, but objective granular assessments of their comparative impact on individuals and the healthcare system are lacking in the literature. The epidemiology, symptomology, and annual public health burden presented by influenza are generally well characterized; however, this is largely through estimates as opposed to comprehensive reporting.[1] The Centers for Disease Control and Prevention (CDC) estimates that over the past 10 years, between 9 and 45 million people have contracted influenza annually in the USA, with annual hospitalizations ranging from 140,000 to 810,000 and annual mortality ranging from 12,000 to 61,000 (between 0.10 and 0.17% of all cases), depending on the severity of the season.[2] Influenza generally achieves community spread nationwide and can strike all age groups, but mortality is consistently higher in patients who are elderly, immunocompromised, and/or have pre-existing comorbidities such as chronic obstructive pulmonary disease, chronic kidney injury, cirrhosis, or cardiac disease.[3-9] Decades of experience with influenza have led to vaccination programs which can mitigate the impact of influenza in years when the predominant circulating strain is accurately predicted.[10] Official CDC counts indicate that over one million people in the USA have contracted COVID-19 between the virus’s first detected cases through April 30, 2020, with over 150,000 hospitalizations and over 63,000 deaths reported as of that date.[11] However, the methods for reporting COVID-19 and influenza cases and outcomes differ in that COVID-19 is directly reported from each state whereas influenza cases are estimates based on reporting from selected hospitals.[1] Moreover, granular comparisons between these two diseases such as rates and duration of respiratory failure (i.e., mechanical ventilation), need for hospitalization, outcomes of those patients without comorbid disease, frequency of non-pulmonary organ injury, and mortality are lacking, yet essential for understanding these two disease processes. In this study, we compared the epidemiology and clinical characteristics of COVID-19 patients admitted to a large tertiary care teaching hospital in March and April of 2020 with those of influenza patients admitted to the same hospital over the prior 5 years.

METHODS

Design

This was a single-center, retrospective study at an urban tertiary care center. We compared patients admitted to the hospital with a positive laboratory test for influenza during five influenza seasons (September–April 2014–2019) to patients with a positive laboratory test for COVID-19 in March and April 2020. This study was reviewed by the Institutional Review Board at Beth Israel Deaconess Medical Center, which determined the study met exempt status. Written informed consent was therefore not required.

Patient Population

Adult (aged >17 years) patients were included if they were admitted to the hospital for confirmed influenza or COVID-19 during the time frames of interest. Patients with influenza or COVID-19 were screened for eligibility by International Classification of Diseases, 10th revision (ICD-10) codes (see Appendix) and/or laboratory-based testing. Of the screened patients, only patients with confirmed positivity by laboratory test during that hospitalization were included. Laboratory diagnosis of influenza and SARS-CoV-2 were carried out through specific real-time reverse transcriptase–polymerase chain reaction (RT-PCR) assays of nasal swab specimens. The ICD-10 codes are displayed in Supplement Table S1.

Study Data Acquisition

Patient data included demographics, personal medical histories (e.g., chronic comorbid conditions), laboratory findings on admission, intensive care unit admission status, intensive care unit length of stay, invasive mechanical ventilation, hospital length of stay, and mortality. Key variables including the presence and duration of invasive mechanical ventilation, comorbidities, and mortality were manually reviewed to verify the data. Specifically, trained research assistants reviewed all individual patient charts to gather comorbidity data. A physician, author RP, reviewed classified reasons for intubation by chart review (see supplemental table S2). If the reason for intubation was not clear, author MD adjudicated the reason for intubation. To compute the volume of admissions between the two diseases, weekly counts of hospital admissions and mechanically ventilated patients were assessed during the peak 2 months of influenza seasons from 2014 to 2019 and from March to April 2020 for COVID-19. All cases for which laboratory testing occurred greater than five days after admission were reviewed to determine if the disease was believed to be nosocomial. For other variables (e.g., laboratory values), a sample of randomly chosen data was verified using manual chart review. Definitions for elements of the data abstraction are displayed in Table S2 in the supplementary materials.

Outcomes

We collected a number of continuous and categorical outcomes. The continuous outcomes included the duration of mechanical ventilation, the duration of the patient’s index hospital stay for that year, the number of weekly admissions, and the number of weekly incident mechanical ventilation. The categorical outcomes included the incidence of mechanical ventilation, shock, renal replacement therapy, hospital readmissions, ICU admissions, and in-hospital mortality, as well as the reason for mechanical ventilation the proportion of patients on mechanical ventilation with no major comorbidities, and the proportion of overall patients with no major comorbidities.

Data Analysis

Continuous data are presented as medians with interquartile ranges and categorical data are presented as counts and percentages. For continuous outcomes, medians were compared using a Wilcoxon rank-sum test. For categorical outcomes, proportions were compared using chi-squared or Fisher’s exact tests, as appropriate. A subgroup analysis was performed on patients intubated for COVID-19 and influenza pneumonia/ARDS. All analyses were done using Stata 14.2 (College Station, TX) and a p value <0.05 was considered statistically significant.

RESULTS

Overview of COVID-19 and Influenza Admissions with Key Outcomes

In total, 1855 patients were identified and 1634 were included in the study (Fig. 1). Of those included in the study, 582 patients had laboratory-confirmed SARS-CoV-2 and 1052 patients had laboratory-confirmed influenza. An overview of admissions, intensive care unit admissions, receipt of mechanical ventilation, and mortality is illustrated per influenza season compared to COVID-19 (Table 1). The total admissions for influenza per eight-month influenza season averaged 210 (95% CI: 150–271) compared to a total of 582 COVID-19 admissions over the 2-month COVID-19 study period. A total of 174 COVID-19 patients who were admitted in March and April 2020 were placed on mechanical ventilation compared to 84 patients admitted over five seasons of influenza. The proportion of admitted patients who received mechanical ventilation was significantly higher for COVID-19 patients compared to that for influenza patients (30% [174/582] versus 8% [84/1052], p< 0.001). One hundred and nineteen patients (20%) admitted in March and April 2020 with COVID-19 died compared to 34 patients (3%) over five seasons of influenza (p<0.001). Figure 2 illustrates the rates of COVID-19 admissions compared to influenza admissions per season in the busiest 2 months of each influenza season. The timing of local social distancing measures for COVID-19 is also indicated in Figure 2. There was a median of 70 (IQR: 13, 1434) COVID-19 patients admitted per week compared to 16 (IQR: 8, 20) during the busiest 2 months of the influenza season (p=0.044). In addition, the number of COVID-19 patients placed on mechanical ventilation per week was 17 (IQR: 4, 34) compared to a median of 1 (IQR: 0, 2) influenza patient (p<0.001).
Figure 1

Patient inclusion/exclusion criteria.

Table 1

Number of Total Patients, Deaths, ICU Admissions, and Patients Requiring Mechanical Ventilation in Five Influenza Seasons (September 2014–May 2019) and the Initial 2 Months (March and April 2020) of COVID-19

SeasonTotal patients, nMortality, n (%)ICU admission, n (%)Mechanical ventilation, n (%)
Influenza (season—September to April: 8 months)
2014–20152265 (2)54 (24)18 (8)
2015–20161343 (2)37 (28)15 (11)
2016–20172157 (3)34 (16)9 (4)
2017–201826810 (4)60 (22)25 (9)
2018–20192099 (4)46 (22)17 (8)
Total105234 (3)231 (22)84 (8)
COVID-19 (season—March to April: 2 months)
2020582119 (20)251 (43)174 (30)

p<0.001 for comparison between total influenza mortality and COVID-19 mortality, comparison between total influenza ICU admissions and COVID-19 admissions, and comparison between total influenza mechanical ventilation and COVID-19 ventilation

Figure 2

Comparison of COVID-19 hospital admissions during the 9 weeks in March–April 2020 and influenza hospital admissions for the peak 9 weeks in five different seasons. The arrow denotes the approximate timing of the “stay at home” order proclaimed by the Governor of Massachusetts on March 24, 2020.

Patient inclusion/exclusion criteria. Number of Total Patients, Deaths, ICU Admissions, and Patients Requiring Mechanical Ventilation in Five Influenza Seasons (September 2014–May 2019) and the Initial 2 Months (March and April 2020) of COVID-19 p<0.001 for comparison between total influenza mortality and COVID-19 mortality, comparison between total influenza ICU admissions and COVID-19 admissions, and comparison between total influenza mechanical ventilation and COVID-19 ventilation Comparison of COVID-19 hospital admissions during the 9 weeks in March–April 2020 and influenza hospital admissions for the peak 9 weeks in five different seasons. The arrow denotes the approximate timing of the “stay at home” order proclaimed by the Governor of Massachusetts on March 24, 2020.

Demographics and Clinical Characteristics

Patient demographics and medical history are summarized in Table 2. Laboratory values for all patients and patients who required mechanical ventilation are displayed in supplement Tables S3 and S4. There were 304 (52%) males admitted with COVID-19 and 481 (46%) males admitted with influenza. The median age for COVID-19 admissions was 66 (IQR: 52, 77) and 68 (IQR: 56, 80) for influenza admissions. The median body mass index for COVID-19 patients was 29.3 (IQR: 25.7, 34.1) compared to 27.3 (IQR: 23.6, 32.3) for influenza. Past medical history is noted between the two groups in Table 2 for the COVID-19 cohort and the 5 seasons of influenza. There were significantly more patients with no major comorbidities in the COVID-19 group than in the influenza patients (113 [19%] vs 90 [9%], p<0.001).
Table 2

Demographics and Past Medical History

All patientsMechanically ventilated patients
COVID-19 (n=583)Seasonal influenza (n=1052)p valueCOVID-19 (n=174)Seasonal influenza (n=84)p value
Demographics
Male: n (%)304 (52)481 (46)0.01396 (55)48 (57)0.765
Age: median years (IQR)66 (52, 77)68 (56, 80)0.00566 (54, 74)68 (57, 81)0.086
Body mass index: median (IQR)*29.3 (25.7, 34.0)27.3 (23.6, 32.3)<0.00130.4 (27.3, 35.5)28.0 (23.3, 32.9)<0.001
Past medical history
No major comorbidities: n (%)113 (19)90 (9)<0.00144 (25)3 (4)<0.001
Cardiovascular disease: n (%)141 (24)373 (35)<0.00137 (21)27 (32)0.058
Respiratory disease (COPD, asthma): n (%)119 (20)299 (28)<0.00129 (17)30 (36)<0.001
Dementia: n (%)69 (12)84 (8)0.01010 (6)5 (6)>0.999
Stroke: n (%)50 (9)90 (9)0.9888 (5)1 (1)0.279
Immunosuppressed (HIV/ AIDS, transplant): n (%)10 (2)96 (9)<0.0013 (2)4 (5)0.220
Hypertension: n (%)352 (60)638 (61)0.915106 (61)48 (57)0.562
Diabetes mellitus: n (%)210 (36)298 (28)0.00169 (39)30 (36)0.542
Renal disease: n (%)110 (19)211 (20)0.56230 (17)15 (18)0.903
Liver disease: n (%)25 (4)73 (7)0.03111 (6)1 (1)0.111
Cancer: n (%)95 (16)278 (27)<0.00132 (18)24 (29)0.063
Morbid obesity (BMI>40)52 (11)77 (8)0.06223 (14)4 (6)0.113
Alcohol use disorder: n (%)33 (6)147 (14)<0.00116 (9)7 (8)>0.999
Tobacco: n (%)107 (18)211 (20)0.40529 (17)22 (26)0.072

*Body Mass Index were missing from 77 patients with COVID-19 and 22 patients with influenza

Demographics and Past Medical History *Body Mass Index were missing from 77 patients with COVID-19 and 22 patients with influenza In patients who received mechanical ventilation, 55% of the COVID-19 patients were male, compared to 57% of the influenza patients. The median age for COVID-19 patients on mechanical ventilation was 66 (IQR: 54, 74), compared with 68 (IQR: 57, 81) for influenza patients on mechanical ventilation. The median body mass index for COVID-19 patients on mechanical ventilation was 30.8 (IQR: 27.3, 36.1) compared to 27.6 (IQR: 23.3, 32.6) for influenza patients. COVID-19 patients who were mechanically ventilated were statistically significantly more likely to not have major comorbidities compared to influenza patients on mechanical ventilation (44 [25%] vs 3 [4%], p<0.001). The reasons for intubation and subsequent mechanical ventilation are displayed in Table 3. Overall, the reasons for intubation in COVID-19 patients were different than those intubated for influenza (p<0.001). Pneumonia and/or acute respiratory distress syndrome (ARDS) was the reason for 94% of intubations in COVID-19 patients, while this accounted for only 56% of intubations in influenza patients. Additionally, no COVID-19 patients received mechanical ventilation due to exacerbation of pre-existing conditions compared to 14% of influenza cases who received mechanical ventilation for this indication.
Table 3

Reasons for Respiratory Failure in Patients with COVID-19 in March–April 2020 Compared to Patients with Influenza in Five Influenza Seasons (September 2014–May 2019)

COVID-19 (n=175)Influenza (n=84)p value
Pneumonia/acute respiratory distress syndrome: n (%)164 (94)47 (56)<0.001

Exacerbation of pre-existing health condition

(e.g., asthma, chronic lung disease, etc.):n (%)

0 (0)12 (14)

Other causes:n (%)

Neurological (e.g., intracranial bleed)

Surgery/procedure

Cardiac arrest

Gastrointestinal hemorrhage

Hemodynamic instability

Trauma

Unknown

Multifactorial causes not deemed to be primarily pneumonia

10 (6)

1 (1)

2 (1)

2 (1)

1 (1)

0 (0)

0 (0)

1 (1)

3 (2)

17 (30)

4 (5)

8 (10)

1 (1)

2 (2)

1 (1)

1 (1)

0 (0)

8 (10)

Reasons for Respiratory Failure in Patients with COVID-19 in March–April 2020 Compared to Patients with Influenza in Five Influenza Seasons (September 2014–May 2019) Exacerbation of pre-existing health condition (e.g., asthma, chronic lung disease, etc.):n (%) Other causes:n (%) Neurological (e.g., intracranial bleed) Surgery/procedure Cardiac arrest Gastrointestinal hemorrhage Hemodynamic instability Trauma Unknown Multifactorial causes not deemed to be primarily pneumonia 10 (6) 1 (1) 2 (1) 2 (1) 1 (1) 0 (0) 0 (0) 1 (1) 3 (2) 17 (30) 4 (5) 8 (10) 1 (1) 2 (2) 1 (1) 1 (1) 0 (0) 8 (10)

Additional Outcomes

Table 4 summarizes additional clinical outcomes including duration of index hospital admission, duration of mechanical ventilation, provision of vasopressor support, and provision of renal replacement therapy. Patients with COVID-19 had a statistically significantly longer median duration of mechanical ventilation than patients with influenza (14.3 [IQR: 7.9, 22.5] vs 3.3 [IQR: 1.7, 7.9] days, p<0.001). Fifty COVID-19 patients (9%) received renal replacement therapy during their hospitalization, compared to 12 (1%) of influenza patients (p<0.001). One hundred and seventy-seven COVID-19 patients (30%) received vasopressor support during their hospitalization, compared to 74 (7%) of influenza patients (p<0.001). Six of the COVID-19 deaths during the 2-month COVID-19 window were patients who had no major comorbidities (1% of total patients), whereas potentially only three deaths during 5 years of influenza seasons were patients without comorbidities (0.3% of total patients). No deaths among those without major comorbidities were reported in the most recent influenza season. Of note, one of the three deaths in the influenza cohort occurred in a patient who presented with and died from widespread arterial and venous thrombus of unclear etiology and had not seen a physician in many years thus making a determination of underlying conditions difficult but was given a default labeling of healthy.
Table 4

Clinical Outcomes in COVID-19 Patients Treated between March and April 2020 and Influenza Patients Treated During five Influenza Seasons (September 2014–May 2019)

OutcomeCOVID-19 Spring, 2020 (n= 582)Influenza 2014–2019 (n =1052)p value
Index hospital length of stay:median days (IQR)8 (4, 16)4 (2, 7)<0.001
Mechanical ventilation:n (%)174 (30)84 (8)<0.001
Time on mechanical ventilation—intubated patients:* median days (IQR)14.3 (7.9, 22.5).3 (1.7, 7.9)<0.001
Time on mechanical ventilation—intubated patients with pneumonia/ARDS:* median days (IQR)14.7 (8.5, 22.7)3.8 (2.0, 12.5)<0.001
Shock - on vasopressors during hospitalization**:n (%)177 (30)74 (7)<0.001
Renal replacement therapy: n (%)50 (9)12 (1)<0.001
Readmitted within 30 days:n (%)29 (5)15 (1)<0.001
Hospital mortality: n (%)119 (20)34 (3)<0.001

*Including reintubation time

**Measured at the encounter level (n=613 for COVID-19; n=1070 for influenza)

Clinical Outcomes in COVID-19 Patients Treated between March and April 2020 and Influenza Patients Treated During five Influenza Seasons (September 2014–May 2019) *Including reintubation time **Measured at the encounter level (n=613 for COVID-19; n=1070 for influenza) In the subgroup analysis of patients with COVID-19 and influenza pneumonia, we found that those with COVID-19 were younger (66 years vs 70 years, p 0.024), had less pre-existing comorbid disease (26% vs 9%, p value 0.009), and had longer time on mechanical ventilation (14.7 days vs 3.8 days, p value <0.001) (Supplementary table S5). Secondly, we evaluated if the cause of death in patients with COVID-19/influenza was directly or indirectly related or unrelated to the virus. Of all the deaths, 98% of deaths were directly or indirectly due to COVID-19 as and 89% of deaths were directly or indirectly due to influenza (supplementary table S6).

DISCUSSION

COVID-19 has been compared to influenza by both health care professionals and the lay public [12-16] but limited detailed objective data are available for comparing and contrasting the impact of these two disease processes on patients and hospitals. We found that admissions for COVID-19 over a 2-month period at our medical center were more than double the total number of admissions for influenza during any 8-month influenza season in the past 5 years. In addition to the larger volume of cases within a much shorter time period, severity of illness and lethality for COVID-19 were also markedly higher than for influenza. We observed more mechanically ventilated COVID-19 patients (i.e., those with severe, life-threatening illness) in a 2-month period than occurred in five entire seasons of influenza combined, and a similar observation was made with patient deaths. Taken together, these findings indicate that COVID-19 causes more severe disease and is more lethal than influenza. COVID-19 resulted in not only a marked increase in the number of mechanically ventilated patients in a short period of time but also a longer median duration of mechanical ventilation within this population. Specifically, 174 patients required mechanical ventilation for COVID-19 with a median duration on the ventilator of 14 days. In contrast, the combined seasons of influenza only resulted in 84 mechanically ventilated patients for a median duration of 3 days. This combination illustrates both the acute severity of disease and the prolonged nature of the respiratory failure that occurs in COVID-19 compared to influenza. COVID-19 caused a substantial number of patients without major comorbid disease to require mechanical ventilation (44 people in 2 months). In contrast, influenza rarely led to mechanical ventilation in patients without underlying comorbidities (3 people over five seasons). In this specific subgroup, five patients with COVID-19 died in the 2-month period compared to one with influenza over 5 years. Pneumonia and acute respiratory distress syndrome were the predominant causes of mechanical ventilation for COVID-19 (94%), whereas this was not the case for influenza (56%). With influenza, the need for mechanical ventilation often developed as a result of exacerbation of a pre-existing health condition such as asthma or chronic obstructive pulmonary disease (COPD), which did not occur in COVID-19. The apparently higher rate of pneumonia and ARDS in our COVID-19 cohort may at least partly explain the more frequent occurrence of respiratory failure and death even in the absence of serious comorbidities. In addition to acute respiratory failure, rates of vasopressor and renal replacement therapy were significantly increased in COVID-19 compared to influenza. The increased disease severity reflected in the rates of acute respiratory failure and other-organ injury paralleled the overall higher lethality of COVID-19 which resulted in 119 deaths in 2 months compared to 34 deaths from influenza over five seasons. The disparity in deaths was driven by both increased volume of cases and increased lethality within that volume in COVID-19 patients. This study did not evaluate organ injuries such as liver failure, neurological injury, and coagulation disorders, all of which have been reported with COVID-19.[17-23] The increase in volume of COVID-19 cases compared to influenza is noted in Figure 2. This increase in patient volume occurred despite the implementation of increasingly stringent social distancing in Boston starting on March 15, 2020,[24] and a statewide stay-at-home advisory starting on March 24, 2020.[25] New cases began to decrease approximately 6 weeks after these measures were taken, though with resurgence of second wave number of cases in Boston started increasing in the month of November. Thus, the overall volume of cases of COVID-19 in this report was likely modified by these measures, whereas these mitigation measures were not taken during any influenza season. Influenza, however, can be modified by the implementation of widespread vaccination programs which are currently not available for COVID-19. Conversely, we are comparing a new pandemic due to COVID-19 to a well-studied endemic influenza entity. While not a focus of this study, the critical care resources required to manage the marked increase and severity of disease in COVID19 included the emergent conversion of surgical and cardiac intensive care units to medical intensive care units, and the conversion of post-anesthesia care units and multiple medical wards to intensive care units. The conversion of any such space to an intensive care unit has not been done for any influenza season. In addition to space conversion, human resources (i.e., staffing models for new intensive care units), personal protective equipment, and increased use of dialysis were all part of the hospital-wide response to the COVID-19 pandemic but we did not compare these to influenza. Future studies may benefit from direct comparisons of resource utilization for the two disease processes. Our study was limited by the evaluation of subjects in one hospital system, though this methodology allowed for granular assessments of differences between diseases. In addition, the true impact of COVID-19 in the absence of social distancing measures remains unclear as these measures were taken early and within weeks of the onset of hospital admissions. This study was conducted on a cohort of symptomatic COVID-19 patients admitted during the early period of the pandemic in the USA and during early surge of cases in Boston. Our admission criteria have not changed over time and we did not admit patients who were asymptomatic. However, some treatment practices have evolved over time such as the increased use of dexamethasone in COVID-19 patients.

CONCLUSIONS

COVID-19 resulted in significantly more weekly hospital admissions over 2 months than in five seasons of influenza in a region with community spread of both diseases. In addition, COVID-19 resulted in a significant increase in the use of mechanical ventilation, an increase in the use of vasopressor support, an increase in the incidence of renal injury, and an increase in mortality. COVID-19 was also significantly more likely to result in mechanical ventilation for those without major comorbidities as compared to influenza. (DOCX 26 kb)
  18 in total

Review 1.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

2.  COVID-19-New Insights on a Rapidly Changing Epidemic.

Authors:  Carlos Del Rio; Preeti N Malani
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

3.  Clinical manifestations and risk factors for mortality of patients with severe influenza during the 2016-2018 season.

Authors:  Wang-Da Liu; Ching-Yuan Yeh; Ming-Chieh Shih; Wang-Huei Sheng
Journal:  Int J Infect Dis       Date:  2020-04-11       Impact factor: 3.623

Review 4.  Influenza virus-related critical illness: pathophysiology and epidemiology.

Authors:  Andre C Kalil; Paul G Thomas
Journal:  Crit Care       Date:  2019-07-19       Impact factor: 9.097

5.  Influenza in patients with cancer after 2009 pandemic AH1N1: An 8-year follow-up study in Mexico.

Authors:  Diego Ángeles-Sistac; Alexandra Martin-Onraet; Patricia Cornejo-Juárez; Patricia Volkow; Carolina Pérez-Jimenez; Diana Vilar-Compte
Journal:  Influenza Other Respir Viruses       Date:  2019-11-20       Impact factor: 4.380

6.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

7.  Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011.

Authors:  Deliana Kostova; Carrie Reed; Lyn Finelli; Po-Yung Cheng; Paul M Gargiullo; David K Shay; James A Singleton; Martin I Meltzer; Peng-Jun Lu; Joseph S Bresee
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

8.  Epidemiology of Hospital Admissions with Influenza during the 2013/2014 Northern Hemisphere Influenza Season: Results from the Global Influenza Hospital Surveillance Network.

Authors:  Joan Puig-Barberà; Angels Natividad-Sancho; Svetlana Trushakova; Anna Sominina; Maria Pisareva; Meral A Ciblak; Selim Badur; Hongjie Yu; Benjamin J Cowling; Clotilde El Guerche-Séblain; Ainara Mira-Iglesias; Lidiya Kisteneva; Kirill Stolyarov; Kubra Yurtcu; Luzhao Feng; Xavier López-Labrador; Elena Burtseva
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

9.  Liver injury in COVID-19: management and challenges.

Authors:  Chao Zhang; Lei Shi; Fu-Sheng Wang
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-04

10.  Hematological findings and complications of COVID-19.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Ismail Elalamy; Efstathios Kastritis; Theodoros N Sergentanis; Marianna Politou; Theodora Psaltopoulou; Grigoris Gerotziafas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2020-05-23       Impact factor: 13.265

View more
  9 in total

1.  Critical Influenza and COVID-19-A Comparative Nationwide Case-Control Study.

Authors:  Emma Larsson; Jesper Eriksson; Mikael Eriksson; Anders Oldner
Journal:  Crit Care Explor       Date:  2022-05-16

2.  Influenza season 2020-2021 did not begin in Finland despite the looser social restrictions during the second wave of COVID-19: A nationwide register study.

Authors:  Ilari Kuitunen
Journal:  J Med Virol       Date:  2021-05-12       Impact factor: 20.693

3.  Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017-2020: a multicenter, retrospective cohort study in Japan.

Authors:  Yuta Taniguchi; Toshiki Kuno; Jun Komiyama; Motohiko Adomi; Toshiki Suzuki; Toshikazu Abe; Miho Ishimaru; Atsushi Miyawaki; Makoto Saito; Hiroyuki Ohbe; Yoshihisa Miyamoto; Shinobu Imai; Tadashi Kamio; Nanako Tamiya; Masao Iwagami
Journal:  Lancet Reg Health West Pac       Date:  2022-01-02

4.  Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.

Authors:  Olulade Ayodele; Kaili Ren; Jing Zhao; James Signorovitch; Michele Jonsson Funk; Julia Zhu; Ying Bao; Kathleen Gondek; Hillary Keenan
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

5.  Not a New Story: Place- and Race-Based Disparities in COVID-19 and Influenza Hospitalizations among Medicaid-Insured Adults in New York City.

Authors:  Renata E Howland; Scarlett Wang; Ingrid Gould Ellen; Sherry Glied
Journal:  J Urban Health       Date:  2022-02-22       Impact factor: 5.801

6.  One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals.

Authors:  Mayssam Nehme; Olivia Braillard; François Chappuis; Delphine S Courvoisier; Laurent Kaiser; Paola M Soccal; Jean-Luc Reny; Frederic Assal; Guido Bondolfi; Aglaé Tardin; Christophe Graf; Dina Zekry; Silvia Stringhini; Hervé Spechbach; Frederique Jacquerioz; Julien Salamun; Frederic Lador; Matteo Coen; Thomas Agoritsas; Lamyae Benzakour; Riccardo Favale; Stéphane Genevay; Kim Lauper; Philippe Meyer; Nana K Poku; Basile N Landis; Stéphanie Baggio; Marwène Grira; José Sandoval; Julien Ehrsam; Simon Regard; Camille Genecand; Garance Kopp; Ivan Guerreiro; Gilles Allali; Pauline Vetter; Idris Guessous
Journal:  J Intern Med       Date:  2022-03-31       Impact factor: 13.068

7.  Viral load and disease severity in COVID-19.

Authors:  Rahul Dnyaneshwar Pawar; Lakshman Balaji; Shivani Mehta; Andrew Cole; Xiaowen Liu; Natia Peradze; Anne Victoria Grossestreuer; Mahmoud Salah Issa; Parth Patel; James Edward Kirby; Christopher Francis Rowley; Katherine Margaret Berg; Ari Moskowitz; Michael William Donnino
Journal:  Intern Emerg Med       Date:  2021-06-16       Impact factor: 5.472

8.  COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.

Authors:  Eng Hooi Tan; Anthony G Sena; Albert Prats-Uribe; Seng Chan You; Waheed-Ul-Rahman Ahmed; Kristin Kostka; Christian Reich; Scott L Duvall; Kristine E Lynch; Michael E Matheny; Talita Duarte-Salles; Sergio Fernandez Bertolin; George Hripcsak; Karthik Natarajan; Thomas Falconer; Matthew Spotnitz; Anna Ostropolets; Clair Blacketer; Thamir M Alshammari; Heba Alghoul; Osaid Alser; Jennifer C E Lane; Dalia M Dawoud; Karishma Shah; Yue Yang; Lin Zhang; Carlos Areia; Asieh Golozar; Martina Recalde; Paula Casajust; Jitendra Jonnagaddala; Vignesh Subbian; David Vizcaya; Lana Y H Lai; Fredrik Nyberg; Daniel R Morales; Jose D Posada; Nigam H Shah; Mengchun Gong; Arani Vivekanantham; Aaron Abend; Evan P Minty; Marc Suchard; Peter Rijnbeek; Patrick B Ryan; Daniel Prieto-Alhambra
Journal:  Rheumatology (Oxford)       Date:  2021-10-09       Impact factor: 7.046

9.  Comparison of clinical and biochemical features of hospitalized COVID-19 and influenza pneumonia patients.

Authors:  Didem Görgün Hattatoğlu; Birsen P Yıldız
Journal:  J Med Virol       Date:  2021-07-29       Impact factor: 20.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.